In its second-quarter earnings release, Exelixis, Inc. EXEL announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed. This study evaluates cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable softtissue disease who have progressed after treatment with one prior NHT. Also Read: Bristol Myers, Exelixis Reveal 4-Year Follow-Up Re ...